Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain

Neuroscience

Volumn 169, Issue 1, 2010, Pages 463-474

  Geis, C ^a   Graulich, M ^a   Wissmann, A ^b   Hagenacker, T ^b   Thomale, J ^b   Sommer, C ^a   Schafers M ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Bone cancer pain; Etanercept; Hyperalgesia; Spinal astrogliosis; TNF receptor 1 and 2; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; FIBROSARCOMA; GENE DELETION; HYPERALGESIA; MALE; MOUSE; NONHUMAN; OSTEOCLAST ACTIVITY; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR GROWTH;

ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; BONE NEOPLASMS; FIBROSARCOMA; GLIOSIS; HYPERALGESIA; IMMUNOGLOBULIN G; LAMENESS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; OSTEOCLASTS; PAIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SPINAL CORD; TOUCH; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953809027     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.04.022     Document Type: Article

References (45)

1. Akassoglou K., Probert L., Kontogeorgos G., Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997, 158:438-445.
2. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2:420-430.
3. Baamonde A., Curto-Reyes V., Juarez L., Meana A., Hidalgo A., Menendez L. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci 2007, 81:673-682.
4. Brounais B., Ruiz C., Rousseau J., Lamoureux F., Blanchard F., Heymann D., Redini F. Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. Recent Pat Anticancer Drug Discov 2008, 3:178-186.
5. Cain D.M., Wacnik P.W., Turner M., Wendelschafer-Crabb G., Kennedy W.R., Wilcox G.L., Simone D.A. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J Neurosci 2001, 21:9367-9376.
6. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63.
7. Constantin C.E., Mair N., Sailer C.A., Andratsch M., Xu Z.Z., Blumer M.J., Scherbakov N., Davis J.B., Bluethmann H., Ji R.R., Kress M. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008, 28:5072-5081.
8. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002, 168:1356-1361.
9. Cunha T.M., Verri W.A., Silva J.S., Poole S., Cunha F.Q., Ferreira S.H. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci U S A 2005, 102:1755-1760.
10. Dixon W. The up-and-down method for small samples. J Am Stat Assoc 1965, 60:967-978.
11. Dunlop R.J., Campbell C.W. Cytokines and advanced cancer. J Pain Symptom Manage 2000, 20:214-232.
12. Eisenthal A., Schwartz I., Issakov J., Klausner Y., Misonzhnik F., Lifschitz-Mercer B. Immunohistochemistry evaluation of the effect in vivo of tumor necrosis factor (TNF)-alpha on blood vessel density in murine fibrosarcoma. Sarcoma 2003, 7:57-61.
13. Fang N., Li Y., Xu Y.S., Ma D., Fu P., Gao H.Q., Gao F.T., Yang H.S., Yang Z.J. Serum concentrations of IL-2 and TNF-alpha in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy. J Nucl Med 2006, 47:242-246.
14. Friedman R. Pain at the cellular level: the role of the cytokine tumor necrosis factor-alpha. Reg Anesth Pain Med 2000, 25:110-112.
15. Fukuda T., Yamaguchi T., Yamaki T., Suzuki T. Ovarian fibrosarcoma producing multiple cytokines. Pathol Int 2001, 51:739-743.
16. Hald A., Nedergaard S., Hansen R.R., Ding M., Heegaard A.M. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J Pain 2009, 13:138-145.
17. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98:585-598.
18. Hundsberger H., Verin A., Wiesner C., Pfluger M., Dulebo A., Schutt W., Lasters I., Mannel D.N., Wendel A., Lucas R. TNF: a moonlighting protein at the interface between cancer and infection. Front Biosci 2008, 13:5374-5386.
19. Inglis J.J., Nissim A., Lees D.M., Hunt S.P., Chernajovsky Y., Kidd B.L. The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Res Ther 2005, 7:R807-R816.
20. John G.R., Lee S.C., Brosnan C.F. Cytokines: powerful regulators of glial cell activation. Neuroscientist 2003, 9:10-22.
21. Junger H., Sorkin L.S. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 2000, 85:145-151.
22. Kato A., Minami K., Ito H., Tomii T., Matsumoto M., Orita S., Kihara T., Narita M., Suzuki T. Oxycodone-induced analgesic effects in a bone cancer pain model in mice. Oncology 2008, 74(Suppl 1):55-60.
23. Luger N.M., Honore P., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., Clohisy D.R., Mantyh P.W. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001, 61:4038-4047.
24. Luger N.M., Sabino M.A., Schwei M.J., Mach D.B., Pomonis J.D., Keyser C.P., Rathbun M., Clohisy D.R., Honore P., Yaksh T.L., Mantyh P.W. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 2002, 99:397-406.
25. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002, 14:477-492.
26. Mantyh P.W., Clohisy D.R., Koltzenburg M., Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002, 2:201-209.
27. Mercadante S., Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998, 24:425-432.
28. Merkel K.D., Erdmann J.M., McHugh K.P., Abu-Amer Y., Ross F.P., Teitelbaum S.L. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999, 154:203-210.
29. Portenoy R.K., Lesage P. Management of cancer pain. Lancet 1999, 353:1695-1700.
30. Rocha A.C., Fernandes E.S., Quintao N.L., Campos M.M., Calixto J.B. Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol 2006, 148:688-695.
31. Rostworowski M., Balasingam V., Chabot S., Owens T., Yong V.W. Astrogliosis in the neonatal and adult murine brain post-trauma: elevation of inflammatory cytokines and the lack of requirement for endogenous interferon-gamma. J Neurosci 1997, 17:3664-3674.
32. Sabino M.A., Ghilardi J.R., Jongen J.L., Keyser C.P., Luger N.M., Mach D.B., Peters C.M., Rogers S.D., Schwei M.J., de Felipe C., Mantyh P.W. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002, 62:7343-7349.
33. Sabino M.A., Luger N.M., Mach D.B., Rogers S.D., Schwei M.J., Mantyh P.W. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. Int J Cancer 2003, 104:550-558.
34. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999, 19:10886-10897.
35. Schweizerhof M., Stosser S., Kurejova M., Njoo C., Gangadharan V., Agarwal N., Schmelz M., Bali K.K., Michalski C.W., Brugger S., Dickenson A., Simone D.A., Kuner R. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 2009, 15:802-807.
36. Selinsky C.L., Howell M.D. Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo. Cell Immunol 2000, 200:81-87.
37. Sorkin L.S., Xiao W.H., Wagner R., Myers R.R. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997, 81:255-262.
38. Thompson S.W., Tonge D. Bone cancer gain without the pain. Nat Med 2000, 6:504-505.
39. Tobinick E.L. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 2003, 25:2279-2288.
40. Vogel C., Stallforth S., Sommer C. Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J Peripher Nerv Syst 2006, 11:294-303.
41. Wacnik P.W., Eikmeier L.J., Ruggles T.R., Ramnaraine M.L., Walcheck B.K., Beitz A.J., Wilcox G.L. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 2001, 21:9355-9366.
42. Wacnik P.W., Eikmeier L.J., Simone D.A., Wilcox G.L., Beitz A.J. Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience 2005, 132:479-491.
43. Wacnik P.W., Kehl L.J., Trempe T.M., Ramnaraine M.L., Beitz A.J., Wilcox G.L. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain 2003, 101:175-186.
44. Wang X., Lin Y. Tumor necrosis factor and cancer, buddies or foes?. Acta Pharmacol Sin 2008, 29:1275-1288.
45. Zhang R.X., Liu B., Li A., Wang L., Ren K., Qiao J.T., Berman B.M., Lao L. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 2008, 154:1533-1538.